AlphaCentric Advisors’s Verona Pharma VRNA Stock Holding History

AlphaCentric Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$753K	Sell	16,211 -33,789	-68%	-$1.27M	0.75%	36
2024 Q3	$1.44M	Sell	50,000 -6,000	-11%	-$148K	1.07%	30
2024 Q2	$810K	Hold	56,000	–	–	0.6%	59
2024 Q1	$901K	Hold	56,000	–	–	0.54%	68
2023 Q4	$1.11M	Hold	56,000	–	–	0.75%	50
2023 Q3	$913K	Buy	56,000 +1,000	+2%	+$19.3K	0.52%	69
2023 Q2	$1.16M	Hold	55,000	–	–	0.65%	57
2023 Q1	$1.1M	Hold	55,000	–	–	0.76%	42
2022 Q4	$1.44M	Buy	55,000 +15,000	+38%	+$200K	1.42%	14
2022 Q3	$409K	Buy	+40,000	New	+$337K	0.42%	65

Other funds holding VRNA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCentric Advisors's VRNA Position: Q4 2024 in Review

AlphaCentric Advisors reduced its Verona Pharma (VRNA) stake by 68% in Q4 2024, selling an estimated $1.27M and leaving 16,211 shares worth $753K. The position accounts for 0.75% of the portfolio, ranked #36.

AlphaCentric Advisors first reported a position in VRNA in Q3 2022 and has held it in 10 quarters since. The position peaked at $1.44M in Q3 2024. 191 funds tracked by Wall St. Rank hold VRNA as of Q4 2024.

AlphaCentric Advisors held 16,211 shares of Verona Pharma worth $753K as of Q4 2024.
AlphaCentric Advisors sold 33,789 Verona Pharma shares in Q4 2024, an estimated $1.27M.
Verona Pharma made up 0.75% of AlphaCentric Advisors's portfolio in Q4 2024, its #36 holding.
AlphaCentric Advisors first reported a position in Verona Pharma in Q3 2022 and has held it in 10 quarters since.
AlphaCentric Advisors's Verona Pharma position peaked at $1.44M in Q3 2024.
191 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.